Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1 (First-In-Human [FIH]), Multi-Site, Dose Escalation and Expansion Study of WTX-330 in Adult Patients with Advanced or Metastatic Solid Tumors or Lymphoma

Principal Investigator: Fountzilas, Christos

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Principal Investigator: McCarthy, Philip L

A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)

Principal Investigator: Pan, Dorothy

An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T…

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

(AHOD2131) A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Principal Investigator: Kelly, Kara M

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta T Cells in Adults with B Cell Malignancies

Principal Investigator: Cortese, Matthew J

A Phase 1 Study to Evaluate the Safety and Tolerability of a 2-component autologous CD19 CAR T cell therapy (STK-009 and SYNCAR-001) in Subjects with Relapsed or Refractory CD19+ Hematologic Malignancies.

Principal Investigator: Cortese, Matthew J

(S1918) A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade…

Principal Investigator: Cortese, Matthew J